M. Boron

Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome.

P. Adamson, R. Murphy, F. Balis, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Carboxypeptidase-G2 (CPDG2) and leucovorin (LV) rescue with and without addition of thymidine (Thd) for high-dose methotrexate (HDMTX) induced renal dysfunction

P. Adamson, F. Balis, B. Widemann, 2005 .

Bevacizumab (BV) plus 5-FU/leucovorin (FU/LV) for advanced colorectal cancer (CRC) that progressed after standard chemotherapies: An NCI Treatment Referral Center trial (TRC-0301).

H X Chen, L. Grochow, M. Mooney, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expanded access trial of tocilizumab in COVID19+hospitalized cancer patients

W. McCaskill-Stevens, B. Freidlin, J. Doroshow, 2020 .

Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2.

R. Hermann, P. Adamson, F. Balis, 2004, Journal of the National Cancer Institute.

Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group

B. Crompton, D. Rakheja, Helen X. Chen, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301.

L. Grochow, L. Rubinstein, C. Jaffe, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early Access to Investigational Agents through the National Cancer Institute's Treatment Referral Center.

M. Boron, T. M. Johnson, 2012, Journal of hematology oncology pharmacy.